Enanta gains $3 over IPO on first trading day
This article was originally published in Scrip
Executive Summary
Enanta Pharmaceuticals launched its initial public offering on 21 March at the low end of its previously announced range of $14 to $16 per share, but the small molecule hepatitis C drug developer's stock closed at $17.21 - a $3.21 gain, or 22.7% premium, over the IPO price.